In vivo (Athens, Greece) · 2025
Initial Experience With Proton Beam Therapy for Pancreatic Cancer at Shonan Kamakura General Hospital.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shiba Shintaro, Shiraishi Sachika, Koizumi Kazuya, Fujimoto Yutaka, Ishiai Naoto, Tokuuye Koichi, Omura Motoko
Аннотация
BACKGROUND/AIM: In Japan, proton beam therapy (PBT) for locally advanced pancreatic cancer was administered under an advanced medical treatment system until 2022; since then, it has been covered by national insurance. Our hospital initiated PBT for pancreatic cancer in July 2022. This study evaluated the clinical outcomes of PBT for pancreatic cancer after the initiation of national insurance coverage and assessed whether our initial experience at our hospital reproduced previously reported results.
PATIENTS AND METHODS: This study included 10 patients with pancreatic cancer confirmed as inoperable due to locally advanced stage, comorbidity, or refusal to undergo surgery, without distant metastasis. All patients received a total PBT dose of 67.5 Gy (relative biological effectiveness) delivered in 25 fractions.
RESULTS: The median follow-up durations for all and surviving patients were 13.9 months (range=3.9-24.6 months) and 19.5 months (range=8.1-24.6 months), respectively. The 1- and 2-year overall survival and local control rates were 70% and 35%, and 89% and 89%, respectively. No grade 3 or higher acute or late non-hematological toxicities associated with PBT were observed.
CONCLUSION: The clinical outcomes at the newly established PBT facility were comparable and reproducible to those observed in patients treated under the previous advanced medical treatment system.
PATIENTS AND METHODS: This study included 10 patients with pancreatic cancer confirmed as inoperable due to locally advanced stage, comorbidity, or refusal to undergo surgery, without distant metastasis. All patients received a total PBT dose of 67.5 Gy (relative biological effectiveness) delivered in 25 fractions.
RESULTS: The median follow-up durations for all and surviving patients were 13.9 months (range=3.9-24.6 months) and 19.5 months (range=8.1-24.6 months), respectively. The 1- and 2-year overall survival and local control rates were 70% and 35%, and 89% and 89%, respectively. No grade 3 or higher acute or late non-hematological toxicities associated with PBT were observed.
CONCLUSION: The clinical outcomes at the newly established PBT facility were comparable and reproducible to those observed in patients treated under the previous advanced medical treatment system.